Get Involved
Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma
Study Purpose
This is a clinical study to compare the efficacy and safety of HBI-8000 combined with nivolumab to Placebo combined with nivolumab in patients with unresectable or metastatic melanoma. A separate open-label cohort of adults with new, progressive brain metastasis or adolescents with or without new progressive brain metastasis receive HBI-8000 combined with nivolumab.
Recruitment Criteria
|
Accepts Healthy Volunteers
Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms |
No |
|
Study Type
An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes. Searching Both is inclusive of interventional and observational studies. |
Interventional |
| Eligible Ages | 12 Years and Over |
| Gender | All |
Inclusion Criteria:
1. Histopathologically confirmed diagnosis of non-uveal, Stage III (unresectable), or Stage IV (metastatic) melanoma according to AJCC staging system (8th edition). 2. Known BRAF V600 mutation status or consent to BRAF V600 mutation testing before randomization. 3. Tumor tissue available for PD-L1 testing at central lab or local laboratory; results must be obtained prior to randomization. In the event when archived tumor tissue is not available, new tumor biopsy or historical PD-L1 test results may be used for randomization, however tumor tissue, either taken previously or newly acquired, must be provided for central biomarker confirmation for final data analyses. PD-L1 expression level is required for randomization. In order to be randomized, a patient must be classified as PD-L1 positive or PD-L1 negative according to the following criteria:- - PD-L1 positive (≥ 1% tumor cell membrane staining in a minimum of a hundred evaluable tumor cells) vs. - PD-L1 negative (< 1% tumor cell membrane staining in a minimum of a hundred evaluable tumor cells).
- - Longest diameter ≥10 mm by CT (when slice thickness is ≤5 mm); or ≥ 2× slice thickness (when slice thickness is >5 mm) - Pathologically enlarged lymph node: ≥15 mm in short axis by CT (when slice thickness is ≤5 mm) - Clinical: ≥10 mm (that can be accurately measured with calipers).
- - BRAF mutation targeting therapy > 4 weeks before administration of Study Treatment.
- - Adjuvant or neoadjuvant therapy with PD-1 or PD-L1 inhibitors or anti-cytotoxic T lymphocyte-associated protein 4 (anti-CTLA-4) is allowed if disease progression/or recurrence had occurred at least 6 months after the last dose of neoadjuvant/adjuvant therapy and prior to receiving the first dose on this study and no clinically significant immune related toxicities leading to treatment discontinuation were observed.
- - Adjuvant interferon therapy must have been completed > 6 weeks before administration of Study Treatment.
- - Hematology: WBC ≥3000/μL, neutrophils ≥1500/μL, platelets ≥100 × 103/μL, hemoglobin ≥10.0 g/dL independent of transfusion.
- - The CrCL≥ 30 mL/min using Cockcroft-Gault formula.
- - AST and ALT ≤3 × ULN, alkaline phosphatase ≤2.5 × ULN unless bone metastases present (patients with documented bone metastases: alkaline phosphatase <5 x ULN), bilirubin ≤ 1.5 × ULN (unless known Gilbert's disease where it must be ≤ 3 × ULN), serum albumin ≥ 3.0 g/dL).
Exclusion Criteria:
1. History of ≥ Grade 3 hypersensitivity reactions to monoclonal antibodies. 2. Previous treatment with a PD-1, PD-L1, PD-L2, CTLA-4 inhibitor, or any other agents targeting T-cell co-stimulation or immune checkpoint pathways for unresectable or metastatic melanoma. 3. Recipient of solid organ transplant. 4. History of a cardiovascular illness including: congestive heart failure (New York Heart Association Grade III or IV); unstable angina or myocardial infarction within the previous 6 months prior to first dose of Study Treatment; or symptomatic cardiac arrhythmia despite medical management. QT interval corrected by heart rate using QTcF >450 ms in males or >470 ms in females, or congenital long QT syndrome. 5. Uncontrolled hypertension, systolic blood pressure (SBP) >160 mmHg or diastolic blood pressure (DBP) >100 mmHg. 6. Patients with new, active, or progressive brain metastases or leptomeningeal disease with except when considered for a separate special open-label cohort. 7. History of hemorrhagic diarrhea, inflammatory bowel disease, active uncontrolled peptic ulcer, or bowel resection that affects absorption of orally administered drugs. 8. Active, known, or suspected autoimmune disease, except for Type I diabetes mellitus, hypothyroidism requiring only hormone replacement, or skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic therapy. 9. Active uncontrolled bacterial, viral, or fungal infection requiring systemic therapy. 10. Known history of testing positive for HIV, known AIDS. 11. Hepatitis B surface antigen positive or hepatitis C antibody positive. Further investigation per institutional practices may be performed to exclude active infection. 12. Patients with a condition requiring chronic systemic treatment with either corticosteroids (>10 mg daily prednisone or equivalents) or other immunosuppressive medications within 14 days before administration of Study Treatment. Inhaled or topical steroids, or adrenal replacement dose of corticosteroids at dose ≤ 10 mg/day prednisone equivalent are permitted. 13. Use of another investigational agent (drug or vaccine not marketed for any indication) within 28 days or before administration of Study Treatment. If the investigational agent is a monoclonal antibody then within 3 months before administration of Study Treatment. 14. Pregnant or breast-feeding women. 15. Have a history of any other malignancy unless in remission for 2 years or locally curable cancers that have been treated with curative intent with no evidence of recurrence, such as:- - Basal or squamous cell skin cancer.
- - Superficial bladder cancer.
- - Carcinoma in situ of cervix or breast.
- - Incidental prostate cancer.
- - Non melanomatous skin cancer.
- - Prostate cancer treated with curative intent with serum prostate specific antigen (PSA) < 2.0 ng/mL.
Trial Details
|
Trial ID:
This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries. |
NCT04674683 |
|
Phase
Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans. Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data. Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use. |
Phase 3 |
|
Lead Sponsor
The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data. |
HUYABIO International, LLC. |
|
Principal Investigator
The person who is responsible for the scientific and technical direction of the entire clinical study. |
Gloria Lee, MD, PhD |
| Principal Investigator Affiliation | HUYABIO International, LLC. |
|
Agency Class
Category of organization(s) involved as sponsor (and collaborator) supporting the trial. |
Industry |
| Overall Status | Active, not recruiting |
| Countries | Australia, Austria, Belgium, Brazil, Czechia, France, Germany, Italy, Japan, New Zealand, Puerto Rico, Singapore, South Africa, South Korea, Spain, United Kingdom, United States |
|
Conditions
The disease, disorder, syndrome, illness, or injury that is being studied. |
Unresectable or Metastatic Melanoma, Progressive Brain Metastasis |
| Study Website: | View Trial Website |
This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 study of HBI-8000 or Placebo combined with nivolumab. Randomization of eligible patients will be stratified by PD-L1 expression (positive, ≥1% expression level versus negative, <1% expression level) and LDH (normal versus elevated) in the main study. Adults with new, progressive brain metastasis, or adolescents with or without new progressive brain metastasis will be enrolled in a separate, non-randomized, open-label cohort to receive the combination of HBI-8000 and nivolumab. In the main study, eligible patients will be randomized within the appropriate stratum at a 1:1 ratio to the Test arm or the Control arm. Study treatment will be initiated within 3 days of randomization. A treatment cycle consists of 28 days. Patients will be treated with one of the following: Test arm: HBI-8000 30 mg oral BIW + nivolumab IV at specific doses on specific days.Control arm: Placebo oral BIW + nivolumab IV at specific doses on specific days.The Study Treatment (HBI-8000 or Placebo) is administered approximately 30 minutes after a full meal. The Study Treatment (HBI-8000 or Placebo) will be administered twice a week on the following days of every 28-day cycle:
- - CxW1: Days 1, 4.
- - CxW2: Days 8, 11.
- - CxW3: Days 15, 18.
- - CxW4: Days 22, 25.
Arms
Experimental: Test Arm
HBI-8000 30 mg oral BIW + nivolumab IV at specific doses on specific days
Placebo Comparator: Control Arm
Placebo oral BIW + nivolumab IV at specific doses on specific days
Interventions
Drug: - HBI-8000 in combination with nivolumab
Patients will take 30 mg of HBI-8000 orally approximately 30 minutes after a full meal, beginning on Day 1 and continue every 3 to 4 days on the BIW schedule. On Day 1 of each cycle nivolumab IV will be administered by intravenous infusion at specific doses on specific days in accordance with OPDIVO® manufacturer regional product information insert and the institution's prescribing practice. In adolescent patients with body weight < 40 kg, nivolumab will be dosed at specific doses on specific days.
Drug: - Placebo in combination with nivolumab
Patients will take 30 mg of Placebo orally approximately 30 minutes after a full meal, beginning on Day 1 and continue every 3 to 4 days on the BIW schedule. On Day 1 of each cycle nivolumab IV at specific doses will be administered by intravenous infusion in accordance with OPDIVO® manufacturer regional product information insert and the institution's prescribing practice.
Contact a Trial Team
If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.
Status
Address
Comprehensive Blood and Cancer Center
Bakersfield 5325738, California 5332921, 93309
Status
Address
UC San Diego Moores Cancer Center
La Jolla 5363943, California 5332921, 92037
Status
Address
Innovative Clinical Research Institute (ICRI)
Pasadena 5381396, California 5332921, 91105
Status
Address
Emad Ibrahim, MD, INC
Redlands 5386754, California 5332921, 92373
Status
Address
Kaiser Permanente Oncology Research
Riverside 5387877, California 5332921, 92505
Status
Address
California Cancer Associates for Research and Excellence, Inc. (cCARE)
San Marcos 5392368, California 5332921, 92069
Status
Address
Boca Raton Regional Hospital, Lynn Cancer Institute
Boca Raton 4148411, Florida 4155751, 33486
Status
Address
Memorial Regional Hospital
Hollywood 4158928, Florida 4155751, 33021
Status
Address
Baptist MD Anderson Cancer Center
Jacksonville 4160021, Florida 4155751, 32207
Status
Address
Orlando Health
Orlando 4167147, Florida 4155751, 32806
Status
Address
Ascension Sacred Heart Medical Oncology
Pensacola 4168228, Florida 4155751, 32504
Status
Address
Moffitt Cancer Center
Tampa 4174757, Florida 4155751, 33612
Status
Address
Goshen Center for Cancer Care
Goshen 4920808, Indiana 4921868, 46526
Status
Address
St. Elizabeth Healthcare
Edgewood 4290873, Kentucky 6254925, 41017
Status
Address
Baptist Health Lexington
Lexington 4297983, Kentucky 6254925, 40503
Status
Address
Frederick Memorial Healthcare System
Frederick 4355585, Maryland 4361885, 21701
Status
Address
St Louis Cancer Care
Bridgeton 4378391, Missouri 4398678, 63044
Status
Address
AMR Kansas City
Kansas City 4393217, Missouri 4398678, 64114
Status
Address
Medisearch Clinical Trials
Saint Joseph 4407010, Missouri 4398678, 64506
Status
Address
St. Vincent - Frontier Cancer Center
Billings 5640350, Montana 5667009, 59102
Status
Address
Levine Cancer Institute
Charlotte 4460243, North Carolina 4482348, 28204
Status
Address
Southeastern Medical Oncology Center
Goldsboro 4468261, North Carolina 4482348, 27534
Status
Address
Gabrail Cancer Center Research
Canton 5149222, Ohio 5165418, 44718
Status
Address
Toledo Clinic Cancer Center
Toledo 5174035, Ohio 5165418, 43623
Status
Address
Thomas Jefferson University Medical Oncology Clinic
Philadelphia 4560349, Pennsylvania 6254927, 19107
Status
Address
AnMed Health
Anderson 4569298, South Carolina 4597040, 29621
Status
Address
Carolina Blood and Cancer Care Associates
Lancaster 4584556, South Carolina 4597040, 29720
Status
Address
Renovatio Clinical
The Woodlands 4736476, Texas 4736286, 77380
Status
Address
Utah Cancer Specialists
Salt Lake City 5780993, Utah 5549030, 84106
Status
Address
Inova Schar Cancer Institute
Fairfax 4758023, Virginia 6254928, 22031
Status
Address
Froedtert Hospital, Medical College of Wisconsin
Milwaukee 5263045, Wisconsin 5279468, 53226
International Sites
Status
Address
Sydney Adventist Hospital
Wahroonga 2145092, New South Wales 2155400,
Status
Address
University of the Sunshine Coast
Buderim 2173605, Queensland 2152274, 4556
Status
Address
Icon Cancer Centre Wesley
South Brisbane 2207259, Queensland 2152274,
Status
Address
Ballarat Health Services
Ballarat 2177091, Victoria 2145234,
Status
Address
Goulburn Valley Health
Shepparton 2149645, Victoria 2145234,
Status
Address
Royal Brisband and Women's Hospital
Brisbane 2174003, ,
Status
Address
Liverpool Hospital
Liverpool 2159851, ,
Status
Address
Affinity Clinical Research
Nedlands 2064874, ,
Status
Address
Tweed Hospital
Tweed Heads 2145765, ,
Status
Address
Calvary Mater Newcastle
Waratah 10103871, ,
Status
Address
Medical University of Graz Department of Dermatology and Venerology
Graz 2778067, , 8036
Status
Address
Univ.-Lkinik für Dermatologie, Venerologie und Allergologie
Innsbruck 2775220, , 6020
Status
Address
AZ Klina
Brasschaat 2801117, , 2930
Status
Address
Cliniques Universitaires
Brussels 2800866, , 1200
Status
Address
AZ Maria Middelares
Ghent 2797656, , 9000
Status
Address
Jessa Ziekenhuis
Hasselt 2796491, , 3500
Status
Address
Hospital de la Citadelle
Liège 2792413, , 4000
Status
Address
Clinique Saint-Pierre
Ottignies 2789570, , 1340
Status
Address
Ensino e Terapia de Inovação Clίnica AMO-ETICA
Salvador 3450554, Estado de Bahia 3471168, 41950-610
Status
Address
Hospital Erasto Gaertner - Liga Paranaense de Combate ao Câncer,
Curitiba 3464975, Paraná 3455077, 81520-060
Status
Address
Hospital do Câncer de Londrina
Londrina 3458449, Paraná 3455077, 86015-520
Status
Address
Hospital São Vicente de Paulo
Centro 9883556, Rio Grande do Sul 3451133, 99010-080
Status
Address
Hospital Bruno Born
Lajeado 3459035, Rio Grande do Sul 3451133, 95900-010
Status
Address
Centro Gaúcho Integrado de Oncologia, Hematologia
Porto Alegre 3452925, Rio Grande do Sul 3451133, 90850-170
Status
Address
Hospital de Clίnίcas de Porto Alegre
Santa Cruz do Sul 3450269, Rio Grande do Sul 3451133, 96810-110
Status
Address
Oncosite-Centro de Pesquisa Clίnica em Oncologia
São Cristóvão, Rio Grande do Sul 3451133, 98700-000
Status
Address
Hopital de Câncer de Barretos-Fundação Pio XII
Barretos 3470451, São Paulo 3448433, 14784-400
Status
Address
Fundação Doutor Amaral Carvalho
Jaú 3460005, São Paulo 3448433, 17210-080
Status
Address
CEPHO-Centro de Estudos e Pesquisas de Hematologia e Oncologia
Santo André 3449701, São Paulo 3448433, 09060-650
Status
Address
Fundação Faculdade Regional de Medicina de São José do Rio Preto
São José do Rio Preto 3448639, São Paulo 3448433, 15090-000
Status
Address
Instituto do Cancer do Estado de São Paulo - "Octavio Frias de Oliveira"-ICESP
São Paulo 3448439, São Paulo 3448433, 01246-000
Status
Address
Fakultni nemocnice Olomoue
Olomouc 3069011, , 77900
Status
Address
Fakultni nemocnice Ostrava Kozni oddeleni
Ostrava-Poruba, , 70852
Status
Address
Fakultni nemocnice Kralovske Vinohrady
Prague 3067696, , 10034
Status
Address
CHU de Besançon - Hôpital Jean MINJOZ
Besançon 3033123, ,
Status
Address
Hôpital Ambroise Paré
Boulogne-Billancourt 3031137, ,
Status
Address
CHU de Dijon, Service de dermatologie
Dijon 3021372, ,
Status
Address
CHU Grenoble Alpes
La Tronche 3006131, ,
Status
Address
CHRU Lille - Hôpital Claude Huriez, Clinique de Dermatologie
Lille 2998324, ,
Status
Address
Hôpital La Timone
Marseille 2995469, , 13385 Cedex 05
Status
Address
Hôpital Saint-Louis
Paris 2988507, ,
Status
Address
Centre Hospitalier Lyon Sud
Pierre-Bénite 2987314, ,
Status
Address
CHU de Rouen-Hôpital
Rouen 2982652, , 76031
Status
Address
Institut Gustave Roussy, Service de Dermatologie
Villejuif 2968705, ,
Status
Address
Charite Universitaetsmedizin Berlin - Campus Charite Mitte
Berlin 2950159, , 10117
Status
Address
Vivantes Klinikum Spandau, Dermatologie und Allergologie
Berlin 2950159, , 13585
Status
Address
Universitaetsklinikum Koeln, Dermatologie und Venerologie,
Cologne 2886242, , 50937
Status
Address
Universitaetsklinikum Carl Gustav Carus TU Dresden, Klinik und Poliklinik f. Dermatologie
Dresden 2935022, , 01307
Status
Address
Helios Klinikum Erfurt, Dermatologie und Allergologie
Erfurt 2929670, , 99089
Status
Address
Universitatsklinikum Essen Klinik fur Dermatologie Studienambulanz
Essen 2928810, ,
Status
Address
Universitaetsklinikum Freiburg, Klinik fuer Dermatologie und Venerologie
Freiburg im Breisgau 2925177, , 79104
Status
Address
Universitaetsklinikum Heidelberg, NCT-Dermatoonkologie
Heidelberg 2907911, , 69120
Status
Address
Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie
Leipzig 2879139, , 04103
Status
Address
Universitaetsklinikum Schleswig Holstein - Campus Luebeck
Lübeck 2875601, , 23538
Status
Address
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz, Hautklinik
Mainz 2874225, , 55131
Status
Address
Universitaetsklinikum Mannheim, Klinik f. Dermatologie, Venerologie, Allergologle,
Mannheim 2873891, , 68167
Status
Address
Studienzentrum Dermao-Onkologie, Universitaetsklinikum Tuebingen
Tübingen 2820860, , 72076
Status
Address
Fondazione IRCCS CA'Granda Ospedale Maggiore Policlinico-Oncologia Medica
Milan 3173435, Milano, 20122
Status
Address
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan 3173435, Milano, 20133
Status
Address
A.O.S. Maria della Misericordia, Oncologia Medica
Perugia 3171180, Perugia, 06132
Status
Address
IRCCS Giovanni Paolo II Oncologia Medica
Bari 3182351, , 70124
Status
Address
Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi IRCCS
Bologna 3181928, , 40138
Status
Address
Humanitas Istituto Clinico Catanese, U.O. Oncologia Medica
Misterbianco 2524123, , 95045
Status
Address
Istituto Nazionale Tumori Fondazione G. Pascale, Oncologia Medica e Terapia Innovativa
Napoli 9031661, , 80131
Status
Address
Azienda Ospedaliero Universitaria Policlinico Paolo Giaccone - U.O. Oncologia Medica
Palermo 2523920, , 90127
Status
Address
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Roma 8957247, , 00168
Status
Address
A.O.U Senese Policlinico Santa Maria alle Scotte-UOC Immunoterapia Oncologica
Siena 3166548, , 53100
Status
Address
Policlinico G.B. Rossi-Borgo Roma-Centro Ricerche Cliniche di Verona
Verona 3164527, , 37134
Status
Address
National Hospital Organization Kyushu Cancer Center
Fukuoka 1863967, Fukuoka 1863958, 811-1395
Status
Address
Shinshu University Hospital
Matsumoto 1857519, Nagano 1856210, 390-8621
Status
Address
Niigata Cancer Center Hospital
Niigata 1855431, Niigata 1855429, 951-8566
Status
Address
Okayama University Hospital
Okayama 1854383, Okayama-ken 1854381, 700-8558
Status
Address
National Hospital Organization Osaka National Hospital
Chuo Ku, Osaka 1853904, 540-0006
Status
Address
Osaka Prefectural Hospital Organization Osaka International Cancer Institute
Osaka 1853909, Osaka 1853904, 541-8567
Status
Address
Shizuoka Cancer Center
Nagaizumi-cho, Sunto-gun, 411-8777
Status
Address
The Cancer Institute Hospital of JFCR
Kōtoku 2128852, Tokho, 135-8550
Status
Address
Auckland City Hospital
Auckland 2193733, ,
Status
Address
Waikato Hospital
Hamilton 2190324, ,
Status
Address
Tauranga Hospital
Tauranga 2208032, , 3112
Status
Address
Hospial Oncologico, Puerto Rico Medical Center
Rio Piedras 4829037, Puerto Rico, 00935
Status
Address
National Cancer Centre
Singapore 1880252, , 169610
Status
Address
The Medical Oncology Centre of Rosebank
Johannesburg 993800, Gauteng 1085594, 2196
Status
Address
Wilgers Oncology Centre
Pretoria 964137, Gauteng 1085594, 0081
Status
Address
Curo Oncology
Pretoria 964137, Gauteng 1085594, 0084
Status
Address
West Rand Oncology Centre Flora Clinic
Roodepoort 936374, Gauteng 1085594, 1709
Status
Address
Excellentis Clinical Trial Consultants
George 1002145, Western Cape 1085599, 6529
Status
Address
Cape Town Oncology Trials Cape Gate Oncology Centre
Kraaifontein 3365083, Western Cape 1085599, 7570
Status
Address
Cancercare Rondebosch Oncology
Rondebosch 7302802, Western Cape 1085599, 7700
Status
Address
National Cancer Center
Goyang-si 1842485, Gyeonggi-do 1841610, 10408
Status
Address
Cha University Bundang Medical Center
Seongnam-si 1897000, Gyeonggi-do 1841610, 13496
Status
Address
Severance Hospital Younsei University Health System,
Seoul, Gyeonggi-do 1841610, 03722
Status
Address
Chonnam National University Hwasun Hospital
Hwasun 1843841, Jeollanam-do 1845788, 58128
Status
Address
Chungnam National University Hospital
Daejeon 1835235, Jung-gu, 35015
Status
Address
Severance Hospital Yonsei University Health System
Seoul 1835848, , 03722
Status
Address
Hospital Universitari Vall d'Hebron
Barcelona 3128760, , 08035
Status
Address
Hospital Clinic de Barcelona
Barcelona 3128760, , 08036
Status
Address
Catalan Institute of Oncology
Barcelona 3128760, , 08908
Status
Address
ICO Badalona-Hospital Universitari Germans Trias I Pujol
Barcelona 3128760, , 08916
Status
Address
Hospital de la Santa Creu i Sant Pau
Barcelona 3128760, ,
Status
Address
MD Anderson Cancer Center
Madrid 3117735, , 28033
Status
Address
Hospital Universitario Fundación Jimenez Diaz
Madrid 3117735, , 28040
Status
Address
Centro Integral Oncologico Clara Campal
Madrid 3117735, , 28050
Status
Address
Hospital Universitario Clinico San Carlos
Madrid 3117735, ,
Status
Address
Hospital Regional Universitario de Málaga
Málaga 2514256, , 29010
Status
Address
Hospital Universitario Virgen Macarena
Seville 2510911, ,
Status
Address
Hospital Universitario Miguel Servet
Zaragoza 3104324, ,
Status
Address
Nuffield Health Wessex Hospital
Eastleigh 2650396, Hampshire, SO53 2DW
Status
Address
Edinburgh Cancer Center Western General Hospital
Edinburgh 2650225, , EH4 2XU
